-
公开(公告)号：US20240238380A1
公开(公告)日：2024-07-18
申请号：US18562322
申请日：2022-05-20
Applicant: YUHAN CORPORATION
Inventor： Seyoung LIM , Ji Eun YANG , Sukyung KIM , Bo Ra SIM , Yunji LEE , Do Hoon KIM , Mi Kyeong JU , Hyun Ho CHOI , Han Na HONG , Junhwan KIM
CPC classification number: A61K38/26 , A61K38/1841 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome by administering in combination with a GLP-1 (glucagon-like peptide-1) receptor agonist, comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.
-
2.发明申请公开(公告)号：US20220024918A1
公开(公告)日：2022-01-27
申请号：US17368712
申请日：2021-07-06
Applicant: YUHAN CORPORATION
Inventor： Tae Dong HAN , Hee Jae TAK , Eun Kyung KIM , Dong Hoon KIM , Su Bin CHOI , Sol PARK , Hyun Ho CHOI , Tae Wang KIM , Mi Kyeong JU , Na Ry HA
IPC: C07D471/04 , C07D519/00
Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
公开(公告)号：US20240279296A1
公开(公告)日：2024-08-22
申请号：US18491616
申请日：2023-10-20
Applicant: YUHAN CORPORATION
Inventor： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
CPC classification number: C07K14/50 , A61P1/16 , A61P3/04 , A61P3/10 , A61K38/1825 , C07K2319/30
Abstract: A fusion protein contains an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
公开(公告)号：US20230002460A1
公开(公告)日：2023-01-05
申请号：US17779932
申请日：2020-11-25
Applicant: YUHAN CORPORATION
Inventor： Seyoung LIM , Young Bong PARK , Sukyung KIM , Bo Ra SIM , Wonee CHONG , Hyun Ho CHOI , Ji Eun YANG , Mi Kyeong JU , Won Tae KIM , Youn Woo LEE , Junhwan KIM
IPC: C07K14/475 , C12N15/63
Abstract: A fusion protein including a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition containing the same are disclosed. The GDF15 variant or long-acting GDF15 fusion protein is superior to conventional GDF15 variants in terms of in vitro efficacy, binding affinity for GDF15 receptors, and body weight loss effect. Therefore, a pharmaceutical composition containing, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or a dimer of the fusion protein, causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity. Furthermore, the pharmaceutical composition can be used in combination therapy or the like with chemical drugs and other therapeutic agents for metabolic diseases, and can be effectively used in combination therapy with conventional therapeutic agents for metabolic diseases or obesity.
-
公开(公告)号：US20220002367A1
公开(公告)日：2022-01-06
申请号：US17478600
申请日：2021-09-17
Applicant: YUHAN CORPORATION
Inventor： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
Abstract: A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
Patent Agency Ranking
公开(公告)号：US20210147368A1
公开(公告)日：2021-05-20
申请号：US17104557
申请日：2020-11-25
Applicant: YUHAN CORPORATION
Inventor： Tae Dong HAN , Hee Jae TAK , Eun Kyung KIM , Su Bin CHOI , Dong Hoon KIM , Sol PARK , Eun Hye JUNG , Hyun Ho CHOI , Tae Wang KIM , Mi Kyeong JU , Na Ry HA
IPC: C07D249/08 , C07D401/04 , C07D403/04 , C07D417/04 , C07D409/10 , C07D405/10 , C07D407/14 , C07D401/10 , C07D403/10 , C07D401/14 , C07D405/14 , C07D417/14 , C07D413/14 , C07D413/10 , C07D417/10 , C07D249/12 , C07D403/14
Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
7.发明申请公开(公告)号：US20200223844A1
公开(公告)日：2020-07-16
申请号：US16712673
申请日：2019-12-12
Applicant: YUHAN CORPORATION
Inventor： Tae Dong HAN , Hee Jae TAK , Eun Kyung KIM , Dong Hoon KIM , Su Bin CHOI , Sol PARK , Hyun Ho CHOI , Tae Wang KIM , Mi Kyeong JU , Na Ry HA
IPC: C07D471/04 , C07D519/00
Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
8.发明申请公开(公告)号：US20230044255A1
公开(公告)日：2023-02-09
申请号：US17368738
申请日：2021-07-06
Applicant: YUHAN CORPORATION
Inventor： Tae Dong HAN , Hee Jae TAK , Eun Kyung KIM , Eui Chul LEE , Sol PARK , Hyok Jun CHO , Cheol Hee LIM , So Young KIM , Hyun Ho CHOI , Da Na JEONG , Na Yeon YANG , Na Ry HA
IPC: C07D403/10 , C07D249/12 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/14
Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
9.发明申请公开(公告)号：US20210317110A1
公开(公告)日：2021-10-14
申请号：US17208887
申请日：2021-03-22
Applicant: YUHAN CORPORATION
Inventor： Tae Dong HAN , Hee Jae TAK , Eun Kyung KIM , Su Bin CHOI , Sol PARK , Dong Hoon KIM , So Young KIM , Hyun Ho CHOI , Tae Wang KIM , Mi Kyeong JU , Na Ry HA , Eui Chul LEE
IPC: C07D409/04 , C07D409/14 , C07D498/04 , C07D413/14 , C07D471/04 , C07D405/14
Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
10.发明申请公开(公告)号：US20200223808A1
公开(公告)日：2020-07-16
申请号：US16721020
申请日：2019-12-19
Applicant: YUHAN CORPORATION
Inventor： Tae Dong HAN , Hee Jae TAK , Eun Kyung KIM , Su Bin CHOI , Dong Hoon KIM , Sol PARK , Eun Hye JUNG , Hyun Ho CHOI , Tae Wang KIM , Mi Kyeong JU , Na Ry HA
IPC: C07D249/08 , C07D401/04 , C07D403/04 , C07D417/04 , C07D409/10 , C07D405/10 , C07D407/14 , C07D401/10 , C07D403/10 , C07D401/14 , C07D405/14 , C07D417/14 , C07D413/14 , C07D413/10 , C07D417/10 , C07D249/12 , C07D403/14
Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.018 seconds)
